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Abstract
Background: Approaches that enhance radiation effect may lead to improved clinical outcome and decrease
toxicity. Here we investigated whether activated CD4+ T cells (aCD4) can serve as an effective radiosensitizer.
Methods: CD4+ T cells were activated with anti-CD3 and anti-CD28 mAbs. Hela cells were presensitized with aCD4
or conditioned supernatant (aCD4S) or recombinant cytokines for 2 days, followed g-irradiation. The treated cells
were cultured for an additional 2 to 5 days for cell proliferation, cell cycle, and western blot assays. For
confirmation, other cancer cell lines were also used.
Results: Presensitization of tumor cells with aCD4 greatly increased tumor cell growth inhibition. Soluble factors
secreted from activated CD4
+ T cells were primarily responsible for the observed effect. IFN-g seemed to play a
major role. TNF-a, though inactive by itself, significantly augmented the radiosensitizing activity of IFN-g. aCD4S,
but not IFN-g or IFN-g/TNF-a combination, was found to enhance the g-irradiation-induced G2/M phase arrest. Bax
expression was highly upregulated in Hela cells presensitized with aCD4S followed by g-irradiation. The radio-
sensitizing activity of aCD4 is not uniquely observed with Hela cell line, but also seen with other cancer cell lines
of various histology.
Conclusions: Our findings suggest possible molecular and cellular mechanisms that may help explain the radio-
sensitization effect of activated lymphocytes, and may provide an improved strategy in the treatment of cancer
with radiotherapy.
Background
Activated T cells elaborate cytokines that are essential
for an effective immune response [1]. These include IL-
2, tumor-necrosis factor (TNF)-a, IL-21 (by activated
CD4
+ T cells), granulocyte/macrophage-stimulating fac-
tor (GM-CSF), interferon (IFN)-g, and other yet known
cytokines. In addition to their immune modulatory
activities, some cytokines also have direct effects on
tumor cells and/or tumor vasculature. TNF-a is known
to induce hemorrhagic necrosis in tumors [2,3]. In addi-
tion, TNF-a has also been shown to induce apoptotic
and necrotic tumor cell death in vitro [4-7]. The hemor-
rhagic necrotic effect is much more potent when used
in combination with chemotherapy in a rat sarcoma
model [8]. However, in these studies TNF-a has no
activity against tumor cell lines in in vitro assays, and
exerts no synergy with chemotherapy or radiotherapy in
this setting [8,9]. The synergistic effect of TNF-a com-
bined with chemotherapy or radiotherapy is directed
mainly against the tumor vasculature [10-12]. The inter-
ferons (IFNs) can exert direct effects on the prolifera-
tion, differentiation, and apoptosis of tumor cells
[13-17]. IFN-g has been shown to enhance the apoptotic
effect of radiation on medulloblastoma cells [18]. How-
ever, responses to the IFNs are considerably variable,
depending on tumor histologies, and resistance to the
IFNs’ effects has been reported in several tumor types
[19-22].
In order to fully utilize the complete repertoire of
cytokines secreted by activated lymphocytes in a simple
yet effective manner, we hypothesize that nonspecifi-
cally-activated CD4
+ lymphocytes (aCD4) can pre-
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any medium, provided the original work is properly cited.sensitize tumor cells to enhance the apoptotic effect of
gamma radiation. The rationale for this strategy is the
known ability of activated T cells to secret multiple dif-
ferent cytokines, which may regulate proliferation and
apoptosis of tumor cells as described above. In addition,
activated T cells may exert direct activity on tumor cells
through apoptotic pathways such as the engagement
of Fas ligand, which is highly expressed on activated
T cells, and Fas receptor on tumor cells.
In this study, we have shown that pre-sensitization of
tumor cells with aCD4 prior to g-irradiation significantly
enhanced cancer cell growth inhibition, and that soluble
factors released by aCD4 were primarily responsible for
the observed activity. IFN-g was found to be the main
cytokine that mediated this effect, and TNF-a, though
inactive by itself, significantly augmented the radiosensi-
tizing activity of IFN-g. We also found that aCD4S, but
not IFN-g or IFN-g/TNF-a combination, enhanced the
g-irradiation induced G2/M phase arrest. In addition,
Bax expression was highly upregulated in Hela cells pre-
sensitized with aCD4S followed by g-irradiation.
Methods
Cell Lines
Human cervical cancer cell lines, Hela and CaSki,
glioma cell lines, LN229 and U373 and prostate cancer
cell line DU145 were obtained from American Type
culture Collection (ATCC; Manassas, VA). All cell
lines were cultured in RPMI 1640 (Mediatech, VA)
supplemented with 10% FBS (Fetal Bovine Serum)
(Atlanta Biologicals, GA), 1 U/ml penicillin and 1 μg/
ml streptomycin (Mediatech) (hereafter referred to
as Complete Medium or CM). All cell lines were
maintained in a humidified incubator at 37°C with
5% CO2.
Isolation and activation of CD4+ T cells (aCD4)
Buffy coat was purchased from regional American Red
Cross. Peripheral blood mononuclear cells (PBMC) were
isolated from the Buffy Coat using Ficoll-Paque Plus
(GE Healthcare, Uppsala, Sweden) and frozen prior to
use. CD4+ T cells were isolated negatively from PBMC,
using the “CD4
+ T cell isolation kit II” (Miltenyi Bio-
t e c h ,C A ) .C D 4
+ T cells were activated immediately
after isolation. The activation was performed over night,
using 24-well plate coated with 5 μg/mL anti-CD3
(OKT3, Orthobiotech, NJ) and 1 μg/mL anti-CD28
(eBioscience, CA), with 300 IU/ml of IL-2. Activated
CD4
+ T cells (aCD4) were harvested, washed and used
immediately for in vitro experiments or labeled with a
FITC-conjugated mouse anti human CD4
+ T cells
(eBioscience) and analyzed for purity by flow cytometry
(FACSVantage, Becton Dickinson, NJ). The activation of
CD4
+ cells was determined by IFNg secretion in an
ELISA assay. All ELISA reagents, monoclonal antibodies
and recombinant cytokines were purchased from Pierce
(Rockford, IL). The ELISA was performed according to
the manufacturer’s instructions.
Generation of conditioned supernatant from aCD4
aCD4 that were activated overnight as described above
were collected, washed, and cultured in 24-well plate at
1×1 0
5,2×1 0
5,o r4×1 0
5 cells/2 ml of CM for 48 hr
to generate conditioned media (hereafter called 5 × 10
4,
1×1 0
5 and 2 × 10
5 aCD4S, respectively). The condi-
tioned media were passed through 0.2 μm filter and
stored at -70°C until use.
Cytokine array
The concentration of thirteen cytokines secreted by
aCD4 was analyzed. CD4+ T cells were activated over-
night as described above, collected, washed, and trans-
ferred to new wells and cultured for another 48 hrs.
The supernatants were collected and sent to “LINCO
Diagnostic Services, Inc.” (St. Charles, MO) for analysis
of 12 common Th1 and Th2 pro-inflammatory and
anti-inflammatory cytokines, including IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IFN-g
and TNF-a. The same supernatants were also used to
determine GM-CSF concentrations, using the “human
GM-CSF ELISA kit” (Pierce, Rockford, IL) according to
the manufacturer’s instructions.
Cell growth inhibition assay
Tumor cells were plated at 4 × 10
4 cells/well with
0.8 ml CM in a 24-well plate overnight. The following
day, 0.8 ml CM containing the indicated doses of aCD4
(direct cell-cell contact or via Transwell system) or
CD4S was added. Forty eight hrs later, tumor cells were
collected and gamma irradiated. In experiments where
recombinant cytokines were used in place of aCD4 or
aCD4S, various combinations of cytokines at similar
concentrations to those detected in the aCD4S derived
from 1 × 10
5 aCD4 cells/mL CM (1 × 10
5 aCD4S) were
used to presensitize tumor cells. The irradiated tumor
cells were plated at 5 × 10
3/well, in triplicate, with
200 μl of 0-25% aCD4S in 96-well plate for 5 days. On
day 5, cell viability was determined using “WST-1 cell
proliferation reagent” (Roche, IN) according to the man-
ufacturer’si n s t r u c t i o n s .F i n a l l y, the absorbance was
measured at 450 nm with an “Opsys MR plate-reader
(Dynex Technologies Inc., VA), and a killing curve was
established. A suboptimal radiation dose that decreased
cell viability by approximately 15-40% was chosen to use
in further experiments, to obtain a large window for
clear observation of the effect, if any, of the experimen-
tal treatment. All experiments were performed in tripli-
cate and repeated at least 2 times.
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For neutralization experiments, monoclonal neutralizing
anti-human IFN-g antibody (eBioscience, CA) was used
to block IFN-g in 1 × 10
5 aCD4S, while mouse IgG1 iso-
type was used as control. Antibodies were added to 1 ×
10
5 aCD4S at 100 μg / m la n dk e p ta tr o o mt e m p e r a t u r e
at least 30 min, then was used to presensitize Hela cells
for 2 days. The presensitized Hela cells were irradiated
with 4 Gy, plated in 96-well plate at 5000 cells/well with
200 μl of fresh CM, and tested cell viability on day 5
using WST-1 reagent.
Cell cycle analysis
Hela cells were plated in 24-well plate at 4 × 10
4/well/
0.8 ml fresh CM overnight, treated with IFN-g,T N F - a,
IFN-g/TNF-a and 1 × 10
5 aCD4S for 48 hrs, followed
by 4 Gy g-irradiation. The irradiated tumor cells were
plated in 24-well plate at 1 × 10
5/well/ml of CM for 2
days. Apoptosis was measured by flow cytometry after
tumor cells were labeled with PI and FITC-conjugated
annexin-V. Flow cytometry was performed on a Becton/
Dickenson FACStar II. Individual fluorescence intensity
values of 20,000 cells were obtained for each sample.
Western blot
Hela cells, resuspended in fresh CM at 5 × 10
5/ml × 5
ml, were plated in T25 flask overnight, treated with 1 ×
10
5 aCD4S for 48 h, followed 4 Gy of g-irradiation, pla-
ted into 6-well plate at 2.5 × 10
5cells/well with 3 ml of
fresh CM for 2 days. The cells were washed twice in
cold PBS and lysed in RIPA lysis buffer (Upstate Cell
Signaling Solutions, NY) and protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO) and PMSF. After incuba-
tion on ice for 30 min, the lysates were centrifuged at
14,000 g at 4°C for 2 min. Protein concentration was
determined by the Pierce Protein BCA Assay (Pierce,
Rockford, IL). For Western blot analysis, 25 μgo fp r o -
tein for each sample was separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and blotted
onto a Hybond ECL nitrocellulose membrane (Amer-
sham Pharmacia Biotech, Freiburg, Germany). Mem-
branes were blocked for 1 h in TBST (Tris-HCl 20 mM,
pH 7.5; NaCl 138 mM; Tween-20 0.1%) containing 5%
non-fat milk at room temperature, probed with primary
antibody for 1 h, washed three times with TBST, probed
again with horseradish peroxidase-conjugated secondary
antibody for 45 min, and washed again three times in
TBST. Antigen-antibody reaction was revealed using
enhanced chemiluminescence (ECL) procedures accord-
ing to the manufacturer’s instructions (Pierce, Rockford,
IL). Bax antibody (Santa Cruz Biotechnology, Santa
C r u z ,C A )w a su s e da t1 : 5 0 0d i l u t i o n .H R P - c o n j u g a t e d
rabbit antimouse IgG (Cell Signaling, Beverly, MA) was
used as a secondary antibody and was diluted at 1:3000.
Statistical analysis
All data are presented as mean values with SD, unless
indicated otherwise. The Student t-test was used to
examine the statistical significance in the difference of
growth assay data. Data were analyzed using the Med-
calc software. P < 0.05 was considered statistically
significant.
Results
Radiosensitizing effect of aCD4 on Hela cells
g-radiation dose-response curves were generated for
each tumor cell line. The cervical carcinoma cell line
Hela was used as our tumor model (Fig. 1A). Based on
this data, a suboptimal g-radiation dose of 4 Gy, which
yielded 27.3% growth inhibition, was selected for use in
aCD4 presensitization experiments.
To investigate whether aCD4 could sensitize Hela cells
to enhance the effect of g-radiation, Hela cells were co-
cultured with indicated doses of aCD4 for 2 days, then
g-irradiated with 4 Gy. Cell viability was determined
using WST-1 assay on Day 5. Hela cell growth was
inhibited by aCD4 in a dose dependent manner (Fig.
1B). Radiation alone resulted in 31.1 ± 2.1% cell growth
inhibition. aCD4 alone, at a dose of 5 × 10
4 or 1 × 10
5/
ml, caused 4.8 ± 3.5% and 10.1 ± 1.9% cell growth inhi-
bition, respectively; while presensitization with 5 × 10
4
or 1 × 10
5 aCD4/mL CM (hereafter called 5 × 10
4 or 1
×1 0
5 aCD4), followed by g-irradiation resulted in 37 ±
1.9% (P < 0.05 versus single agent, irradiation or aCD4
alone) and 53.3 ± 1.7% (P < 0.001 versus single agent)
cell growth inhibition, respectively.
To investigate the contribution of cell-cell contact ver-
sus soluble factor(s) in the radiosensitization of tumor
cells, a permeable transwell system was used to avoid
the contact between tumor cells and aCD4. Similar
degrees of growth inhibition were seen using the trans-
well system. In this system, 4 Gy irradiation alone, 5 ×
10
4 aCD4 alone, or 1 × 10
5 aCD4 alone caused 25.8 ±
3.3%, 11.8 ± 2.6% and 31.5 ± 11.3% cell growth inhibi-
tion, respectively; while presensitization with 5 × 10
4 or
1×1 0
5 aCD4 via transwell, followed by g-irradiation
resulted in 32.2 ± 2.2% and 60.5 ± 1.3% cell growth
inhibition, respectively. Compared with 4 Gy irradiation
alone, a significant decrease in percentage of viable cells
w a ss e e ni nt h e1×1 0
5 aCD4 plus irradiation group
( P<0 . 0 1 )( F i g .1 C ) .T oc o n f i r mt h a ts o l u b l ef a c t o r s
were responsible for the observed activity, we examined
the radiosensitizing effect of cell-free supernatants from
aCD4 on Hela cells. Cell-free supernatants were col-
lected from aCD4 after 48 h (hereafter called aCD4S).
Hela cells were treated with aCD4S for 2 days, followed
with 4 Gy g-irradiation, and plated in a 96-well plate for
cell viability assay on Day 5. Similar results were
obtained as those in aCD4 and Hela cell-cell direct
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7.1% and 32.9 ± 6.8% cell growth inhibition were seen
in the 4 Gy irradiation alone, 5 × 10
4 or 1 × 10
5 aCD4S
alone groups, respectively, while 53.4 ± 10.4% and 62.6
± 1.0% cell growth inhibition were obtained when Hela
cells were presensitized with 5 × 10
4 aCD4S or 1 × 10
5
aCD4S, respectively, followed by 4 Gy irradiation. Com-
pared with 4 Gy of irradiation alone, a significant
decrease in cell viability was seen in the combination of
5×1 0
4 or 1 × 10
5 aCD4S and irradiation groups (P <
0.05 and P < 0.01, respectively, versus single agent) (Fig.
1D). These data confirmed the role of aCD4, particularly
soluble factors released from these cells, in sensitizing
tumor cells to greatly augment the antitumor activity of
g-irradiation.
aCD4 radio-sensitizing activity is irradiation dose
dependent
The data from Fig. 1 demonstrated the aCD4 dose
dependent effect on the observed activity. Here we also
demonstrated that the observed activity was also depen-
dent on g-irradiation doses. The survival fractions of
Hela cells treated with 4 Gy, 6 Gy, or 8 Gy g-irradiation
alone were 88.51 ± 4.33%, 61.6 ± 5.9%, and 39.1 ± 4.1%,
respectively; while those of Hela cells presensitized
with 1 × 10
5 aCD4S, followed by the same doses of
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Figure 1 Radiosensitizing effect of aCD4 on Hela cells.( A) g-irradiation dose response curve. Hela cells were treated with various doses of g-
irradiation, plated at 5 × 10
3/well in 96-well plate containing 200 μl CM and cell viability was determined on day 5. (B, C, D) Suboptimal
radiation dose of 4 Gy was chosen for subsequent experiments with aCD4 presensitization. On day -2, Hela cells were pre-sensitized with 1 ×
10
4 aCD4 [aCD4 (1)] or 2 × 10
4 aCD4 [aCD4 (2)]. The cells were co-cultured directly with aCD4 (B), or via transwell system (C), or treated with
conditioned medium (aCD4S) (D), followed (or not) on day 1 by 4 Gy g-irradiation. Cell growth inhibition was determined on day 5 by WST-1
assay. All experiments were performed in triplicate and repeated at least 2 times. Data represent mean values of each triplicate ± S.D. Groups
labeled ** (P < 0.01) were compared to irradiation alone group.
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Page 4 of 13g-irradiation were 53.8 ± 6.8%, 35.5 ± 5.5%, 26.1 ± 1.3%,
respectively. The difference between irradiation alone
and irradiation plus aCD4S was significant at each irra-
diation doses (P < 0.01) (Fig. 2).
Confirmation of the radiosensitizing effect of aCD4 on the
radioresistant glioma cell line LN229
To assess whether the radiosensitizing activity of aCD4
was unique to Hela cervical cancer cell line, similar
experiments were carried out using the human glioma
cell line LN229. Based on radiation dose response curve
(Fig. 3A) and optimal presensitization condition for
LN229, 6 Gy g-irradiation was used instead of 4 Gy.
This dose alone caused 14.6 ± 2.9% cell growth inhibi-
tion. LN229 cells were presensitized with aCD4 cells in
a cell-cell direct contact manner, or via transwell sys-
tem, or as cell-free conditioned medium (aCD4S) for 2
days, followed by 6 Gy g-irradiation. After irradiation,
the cells were cultured in CM containing 25% aCD4S
for 5 days, and cell viability was measured using WST-1
reagent. In a cell-cell direct contact system, 6 Gy g-irra-
diation alone, 5 × 10
4 aCD4 alone or 1 × 10
5 aCD4
alone caused 20.5 ± 6.0%, 10.0 ± 3.2% and 15.4 ± 3.4%
cell growth inhibition, respectively; while presensitiza-
tion with 5 × 10
4 or 1 × 10
5 aCD4, followed by 6 Gy g-
irradiation resulted in 32.7 ± 9.0% and 52.0 ± 0.8% cell
growth inhibition, respectively. There was significant dif-
ference between the 1 × 10
5 aCD4 plus irradiation ver-
sus single agent, irradiation or aCD4 alone (P < 0.001
for both) (Fig. 3B). In the transwell system, 6 Gy g-irra-
diation alone, 5×10
4 aCD4 alone or 1 × 10
5 aCD4 alone
caused 16.3 ± 6.1%, 13.4 ± 7.2% and 14.9 ± 1.3% cell
growth inhibition, respectively; while presensitization
with 5 × 10
4 or 1 × 10
5 aCD4 via transwell, followed by
6G yg-irradiation resulted in 26.7 ± 6.4% and 44.7 ±
6.7% cell growth inhibition, respectively. Compared sin-
gle agent, irradiation or aCD4 alone, the 1 × 10
5 aCD4
plus irradiation groups significantly reduced LN229 cell
viability (P < 0.01 for both) (Fig. 3C). In the aCD4S sys-
tem, 6 Gy g-irradiation alone, 5 × 10
4 aCD4S alone or 1
×1 0
5 aCD4S alone caused 20.5 ± 6.0%, 23.4 ± 2.3% and
47.4 ± 2.9% cell growth inhibition, respectively; while
presensitization with 5 × 10
4 or 1 × 10
5 aCD4S,
followed by g-irradiation resulted in 57.1 ± 2.3% and
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Figure 2 aCD4 radio-sensitizing activity is irradiation dose dependent. On day -2, Hela cells were pre-sensitized with or without
conditioned medium (aCD4S) for 2 days then g-irradiated on day 1 with various doses. The cells were plated at 5 × 10
3/well in 200 μl in 96-well
plate. Cell growth inhibition was determined on day 5 by WST-1 assay. All experiments were performed in triplicate and repeated at least 2
times. Data represent mean values of each triplicate ± S.D.
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Page 5 of 1371.7 ± 0.8% cell growth inhibition, respectively (P <
0.001 versus single agent for both) (Fig. 3D). The data
demonstrated that aCD4, whether as whole cells cocul-
tured directly with LN229 tumor cells (Fig. 3B) or via
transwell membrane (Fig. 3C), or as cell free condi-
tioned medium (aCD4S) (Fig. 3D), significantly
enhanced the cell growth inhibition effect of g-
irradiation.
Role of cytokines in the radiosensitization of tumor cells
To understand the soluble factors involved in the
observed activity, the aCD4 supernatants (aCD4S) were
screened for the presence of 13 common Th1 and Th2
pro-inflammatory and anti-inflammatory cytokines as
described in materials and methods, and were found to
contain various concentrations of IL-2, IL-4, IL-6, IL-8,
IL-10, IL-12p40, IL-13, IFN-g,T N F - a and GM-CSF
(data not shown). Presensitization of Hela cells with the
combination of these cytokines, at concentrations
equivalent to those in the supernatants of 1 × 10
5
aCD4S, significantly enhanced the growth inhibition
effect of g-irradiation (Fig. 4).
Of the 10 cytokines tested, only IFN-g was found to
significantly enhance the radiosensitivity of irradiation
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Figure 3 Confirmation of the radiosensitizing effect of aCD4 on the radioresistant glioma cell line LN229. (A) g-irradiation dose response
curve. LN229 cells were treated with various doses of g-irradiation, plated at 5 × 10
3/well in 200 μl CM in 96-well plate and cell viability was
determined. (B, C, D) Suboptimal radiation dose of 6 Gy was chosen for subsequent experiments with aCD4 pre-sentization. On day -2, LN229
cells were pre-sensitized with 1 × 10
4 aCD4 [aCD4 (1)] or 2 × 10
4 aCD4 [aCD4 (2)]. The cells were co-cultured directly with aCD4 (B), or via
transwell system (C), or treated with conditioned medium (aCD4S) (D), followed (or not) on day 1 by 6 Gy g-irradiation. Cell growth inhibition
was determined on day 5 by WST-1 assay. All experiments were performed in triplicate and repeated at least 2 times. Data represent mean
values of each triplicate ± S.D. Groups labeled ** (P < 0.01) were compared to irradiation alone or aCD4 alone.
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as well as IFN-g blockade experiments in the presensiti-
zation process to further confirm the essential role of
IFN-g in the observed activity. 4 Gy of g-irradiation
alone, IFN-g alone, combination of all 10 cytokines pre-
viously described (Cyt), or 1 × 10
5 aCD4S alone caused
18.2 ± 3.5%, 21.4 ± 2.2%, 26.6 ± 6.1%, and 9.0 ± 1.1%
cell growth inhibition, respectively. When Hela cells
were presensitized with IFN-g,C y t ,o ra C D 4 S ,f o l l o w e d
by 4 Gy g-irradiation, the cell growth inhibition was
significantly increased to 46.3 ± 0.8% (P < 0.001 versus
single agent), 52.3 ± 0.7% (P < 0.001 and P < 0.01 versus
irradiation and aCD4S, respectively), and 45.9 ± 0.5%
(P < 0.001 versus single agent).
In order to confirm the principal role of IFN-g,i tw a s
omitted from Cyt (Cyt-IFN-g), and the radiosensitization
effect of the cytokine combination was lost, with 15.9 ±
3.6% cell growth inhibition observed versus 18.2 ± 3.5%
for 4 Gy g-irradiation alone (P > 0.05) (Fig. 4). To con-
firm our results, anti-IFN-g monoclonal antibody (anti-
IFN-g) was used to block IFN-g’s activity in aCD4S, with
IgG1 isotype antibody as control (Isotype). Treatment of
Hela cells with 1 × 10
5 aCD4S pre-incubated with anti-
IFN-g,f o l l o w e db y4G yg-irradiation, abolished the
radiosensitization effect of 1 × 10
5 aCD4S, resulting in
12.9 ± 4.4% cell growth inhibition versus 18.2 ± 3.5%
for 4 Gy g-irradiation alone (P > 0.05). The cell growth
inhibition was 43.7 ± 0.5% for 1 × 10
5 aCD4S pre-incu-
bated with Isotype plus 4 Gy g-irradiation and 45.9 ±
0.5% for 1 × 10
5 aCD4S plus 4 Gy g-irradiation (for
both, P < 0.01 versus single agent alone) (Fig 4).
Enhancement of radiosensitizing effect of IFN-g by TNF-a
For these experiments, 80 U/ml of IFN-g and 5.6 ng/
ml of TNF-a, concentrations equivalent to those in
1×1 0
5 aCD4S, were used. TNF-a by itself had no
radiosensitizing activity. The treatment of Hela cells
with TNF-a, followed by 4 Gy irradiation resulted in
growth inhibition of 34.3 ± 5.1% vs. 41.6 ± 2.5% for
irradiation alone (P > 0.05). In contrast, treatment with
IFN-g, followed by 4 Gy irradiation resulted in growth
inhibition of 58.0 ± 2.1% (P < 0.01 versus irradiation
or IFN-g alone). Interestingly, when combined with
IFN-g,T N F - a significantly augmented the
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Figure 4 Role of cytokines in the radiosensitization of tumor cells. On day -2, Hela cells were pre-treated for 2 days with IFN-g; combination
of 10 cytokines, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-13, IFN-g, TNF-a and GM-CSF, (Cyt); combination of cytokines without IFN-g (Cyt-IFN); aCD4S;
or combination of cytokines in the presence of neutralizing anti-IFN-g antibody. On day 1, the cells were treated (or not) with 4 Gy g-irradiation.
Cells were plated in 96-well plate at 5 × 10
3 cells/well in 200 μl CM and cell growth inhibition was determined on day 5 by WST-1 assay. All
experiments were performed in triplicate and repeated at least 2 times. Data represent mean values of each triplicate ± S.D.
Wang et al. BMC Cancer 2010, 10:60
http://www.biomedcentral.com/1471-2407/10/60
Page 7 of 13radiosensitizing effect of IFN-g in Hela cells. Cell
growth inhibition for IFN-g +T N F - a followed by irra-
diation was 78.5 ± 0.6% versus 41.6 ± 2.5% for irradia-
tion alone versus 25.8 ± 5.7% for IFN-g +T N F - a alone
(P < 0.001 for both). The difference between the IFN-g
+T N F - a followed by irradiation group and the IFN-g
followed by irradiation group was statistically signifi-
cant (P < 0.001). The combination of all 10 cytokines
as described previously (Cyt) and aCD4S were used as
positive controls (P < 0.001 versus single agent treat-
ment for both) (Fig. 5).
Effect of aCD4 and cytokine presensitization
on the redistribution of cell cycle phases and
apoptosis of Hela cells
To investigate the mechanism underlying cell growth
inhibition in our model, flow cytometric analysis was
performed to assess the redistribution of cell cycle
phases and apoptosis of Hela cells. Cell cycle analysis
indicated IFN-g,I F N - g/TNF-a combination, or aCD4S
shifted Hela cells into S-phase; while TNF-a alone had
no effect, and TNF-a did not contribute to the activity
seen with the IFN-g/TNF-a combination. 4 Gy of g-irra-
diation induced G2/M-phase arrest in Hela cells. While
the presensitization of Hela cells with IFN-g,T N F - a,o r
IFN-g/TNF-a combination before the g-irradiation did
not affect g-radiation induced G2/M-phase arrest,
presensitization of Hela cells with aCD4S increased the
g-irrradiation-induced G2/M-phase arrest from 28.2% to
40.8% (Fig. 6).
Apoptosis analysis was performed two days after irra-
diation (as opposed to five days for cell viability assay).
As shown in Fig. 7, the percentage of apoptosis was 7.15
± 0.63% with 4 Gy g-irradiation alone, 4.70 ± 0.57%,
respectively, with 5 × 10
4 aCD4 alone, with 1 × 10
5 aCD4
alone, while the numbers increased to 10.30 ± 1.56% in 5
×1 0
4 aCD4 plus 4 Gy of irradiation, and 15.65 ± 4.60%
in 1 × 10
5 aCD4 plus irradiation. The differences were
significant (p < 0.05) for 1 × 10
5 aCD4 plus 4 Gy group
versus irradiation alone or aCD4 alone (Fig. 7).
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Figure 5 Enhancement of radiosensitizing effect of IFN-g by TNF-a. On day -2, Hela cells were pre-sensitized for 2 days with IFN-g,T N F - a,
IFN-g+TNF-a, combination of 10 cytokines (Cyt), or aCD4S, followed (or not) on day 1 with 4 Gy g-irradiation. Cells were then plated in 96-well
plate at 5 × 10
3 cells/well in 200 μl CM and cell growth inhibition was determined on day 5 by WST-1 assay. All experiments were performed in
triplicate and repeated at least 2 times. Data represent mean values of each triplicate ± S.D.
Wang et al. BMC Cancer 2010, 10:60
http://www.biomedcentral.com/1471-2407/10/60
Page 8 of 13aCD4 presensitization followed by irradiation enhanced
Bax expression
To further investigate the mechanisms underlying the
radiosensitizing activity of aCD4, western blot analysis
was performed to evaluate the expression of the pro-
apoptotic protein Bax. There was a slight increase in
Bax expression when Hela cells were treated with
aCD4S alone, compared with no treatment or g-irradia-
tion alone groups. However, Bax expression was highly
upregulated in Hela cells presensitized with aCD4S fol-
lowed by g-irradiation (Fig. 8).
General Role of aCD4 or IFN-g/TNF-a combination in the
radio-sensitization of cancer cells
To assess the generality of aCD4 or IFN-g/TNF-a com-
bination as a radiosensitizer, we tested our approach on
the cervical carcinoma cell line Caski, prostate carci-
noma cell line DU145 and glioma cell line U373. Radia-
tion dose response curves were generated for each cell
line (data not shown). aCD4S or the combination of 160
U/ml of IFN-g and 11.2 ng/ml of TNF-a were used to
presensitize tumor cells for 48 hrs, followed by irradia-
tion. Significant enhancement of cell growth inhibition
was seen in each case (Fig. 9). In Caski cells, 4 Gy of g-
irradiation alone, 2 × 10
5 aCD4S alone or IFN-g/TNF-a
alone caused 26.2 ± 7.3%, 28.6 ± 6.3% and 61.3 ± 8.2%
cell growth inhibition, respectively; while presensitiza-
tion with 2 × 10
5 aCD4S or IFN-g/TNF-a, followed by
g-irradiation resulted in 46.0 ± 4.7% (P < 0.05 versus
irradiation alone) and 73.6 ± 4.4% (P < 0.001 versus irra-
diation alone) cell growth inhibition, respectively (Fig.
9A). In Du145 cells, 4 Gy of g-irradiation alone, 2 × 10
5
aCD4S alone or IFN-g/TNF-a alone caused 42.9 ± 7.9%,
6.0 ± 2.6% and 10.9 ± 0.1% cell growth inhibition,
respectively; while presensitization with 2 × 10
5 aCD4S
or IFN-g/TNF-a, followed by g-irradiation resulted in
54.1 ± 6.8% and 50.4 ± 6.3% cell growth inhibition,
respectively. Compared with irradiation alone, aCD4S
alone and IFN-g/TNF-a alone treatments, aCD4S and
IFN-g/TNF-a combined with irradiation clearly inhib-
ited the cell growth (P < 0.05) (Fig. 9B). In U373 cells,
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Figure 6 Effect of aCD4 and cytokine presentization on the redistribution of cell cycle phases in Hela cells.R e p r e s e n t a t i v ef l o w
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percentage of cells in G0/G1, G2/M or S-phase of the cell cycle is indicated under each curve. These experiments were repeated at least 2 times.
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Page 9 of 13IFN-g/TNF-a alone caused 33.2 ± 5.2%, 15.2 ± 3.8% and
25.0 ± 0.3% cell growth inhibition, respectively; while
presensitization with 2 × 10
5 aCD4S and IFN-g/TNF-a,
followed by g-irradiation resulted in 59.3 ± 6.8% and
60.3 ± 7.5% cell growth inhibition. Compared with irra-
diation alone, aCD4S alone and IFN-g/TNF-a alone
treatments, aCD4S and IFN-g/TNF-a combined with
irradiation markedly inhibited the cell growth (P < 0.01
for both) (Fig. 9C). The results showed either aCD4S or
the combination of IFN-g/TNF-a could increase the
radiosensitivity of these cancer cell lines to g-irradiation.
Discussion
We have demonstrated that pre-sensitization of tumor
cells with non-specifically activated CD4
+ Tc e l l s
greatly enhanced the apoptotic effect of g-irradiation,
and that soluble factors secreted from the activated
CD4
+ T cells were primarily responsible for the
Bax
Control 4Gy aCD4S aCD4S
+4Gy
-tubulin
Figure 8 aCD4S presensitization followed by irradiation
enhanced Bax expression. Hela cells were plated in T25 flask at 5
×1 0
5/well/5 ml CM overnight, treated with aCD4S for 2 days,
followed by 4 Gy g-irradiation, plated into 6-well plate at 2.5 ×
10
5cells/well with 3 ml CM for 2 additional days. Western blot
analysis was performed to evaluate the expression of the pro-
apoptotic protein Bax.
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Figure 7 Effect of aCD4 and cytokine presensitization on apoptosis in Hela cells. Hela cells were pre-treated for 2 days with 1 × 10
4 aCD4
[aCD4 (1)] or 2 × 10
4 aCD4 [aCD4 (2)], followed (or not) by 4 Gy g-irradiation. Tumor cells were labeled with FITC-conjugated annexin-V and PI
and analyzed by flow cytometry. All experiments were repeated at least 2 times. Data represent mean values of each triplicate ± S.D.
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Page 10 of 13observed effect. Of a number of Th1 and Th2 cyto-
kines tested, IFN-g seemed to play a major role in the
radiosensitization of tumor cells. TNF-a,t h o u g hi n a c -
tive by itself, significantly augmented the radiosensitiz-
ing activity of IFN- g.a C D 4 S ,b u tn o tI F N - g or IFN-g/
TNF-a combination, was found to enhance the g-irra-
diation-induced G2/M phase arrest. In addition, Bax
expression was highly upregulated in Hela cells presen-
sitized with aCD4S followed by g-irradiation. The
radio-sensitizing activity of aCD4 is not uniquely
observed in Hela cell line, but also in multiple other
cell lines, including two glioma, one prostate, and
another cervical cancer cell line.
Results from recent studies may also help provide
other possible mechanisms that underlie the radio-sensi-
tizing effect of aCD4. Inflammation and inflammatory
cytokines were shown to generate nitric oxide (NO)
through the induction of nitric oxide synthase, resulting
in global inhibition of DNA repair activity in cholangio-
carcinoma cells [23]. Other studies demonstrated that
IFN-b or IL-24 down-regulated the DNA repair enzyme
O6-methylguanine-DNA methyltransferase expression
and activity in neuroblastoma and melanoma, respec-
tively [24,25].
Interestingly, in our model while TNF-a had no direct
cell inhibition effect either by itself or with radiation
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Figure 9 General role of aCD4 or IFN-g/TNF-a combination in the radio-sensitization of cancer cells. Cancer cells from various histology
were pre-treated with aCD4S or the combination of 160 U/ml of IFN-g and 11.2 ng/ml of TNF-a were used to presensitize tumor cells for 3
days, followed by irradiation (4 Gy for a cervical cell line CaSki and prostate cancer cell line DU145, and 8 Gy for a glioma cell line U373). Similar
results were seen in two independent experiments. All experiments were performed in triplicate and repeated at least 2 times. Data represent
mean values of each triplicate ± S.D. Groups labeled * (p < 0.05) and ** (P < 0.01) were compared to irradiation alone group.
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Page 11 of 13treatment, TNF-a was found to significantly enhance
IFN-g’ radio-sensitizing activity when used in combina-
tion with IFN-g. The reason for this effect is not clear.
However, induction of NO and its subsequent release
may be one of the underlying mechanisms. The addition
of anti-TNF-a blocking antibody to murine macrophage
cell lines prior to irradiation has been shown to inhibit
NO induction by IFN-g [26]. In addition, the combina-
tion of IL-1b, TNF-a, and IFN-g, was shown to generate
NO through the induction of NO synthesis [23]. NO
has been shown to involve in DNA damage and inhibi-
tion of DNA repair [23,27].
Previous studies have shown that IFN-g treatment
reduced the expression of bcl-2 but did not alter that of
Bax [28,29]. Our findings revealed that Bax levels were
slightly increased in Hela cells with aCD4S treatment
alone but substantially upregulated with aCD4S presen-
sitization followed by g-irradiation. Therefore, it is possi-
ble that the combination of bcl-2 reduction and Bax
elevation, resulting in a greatly decreased bcl-2/Bax
ratio, also plays a major role in tumor cell growth inhi-
bition and enhanced apoptosis observed in our model.
Irradiation induced G2/M arrest in most cells [30].
Our data supported this finding. In addition, we have
also shown that pre-treatment of tumor cells with con-
ditioned supernatant from activated CD4
+ T cells
(aCD4S) enhanced irradiation’s effect on the cell cycle
arrest in G2/M phase, which is also the cell cycle phase
in which tumor cells are most sensitive to the DNA
damaging effect from irradiation [31].
Conclusion
Our finding showed that activated CD4
+ T cells
enhanced radiation effect through the cooperation of
interferon-g and TNF-a. The study also suggest possible
molecular and cellular mechanisms that may help
explain the radio-sensitization effect of activated lym-
phocytes, and may provide an improved strategy in the
treatment of cancer with radiotherapy.
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